Abstract
Lysophospholipids (LPLs), including glycerol- and sphingoid-based lipids, stimulate cell signaling and play important pathophysiological roles in humans and other animals. These LPLs include lysophosphatidic acid (LPA), lysophosphatidylinositol (LPI), lysophosphatidylcholine (LPC), lysophosphatidylserine (LPS), sphingosine-1-phosphate (S1P), and sphingosylphosphorylcholine (SPC). Analyses of LPLs in human body fluids from subjects with different pathophysiological conditions reveal not only the relevance of LPLs in human diseases, but also their potential application as biomarkers and / or therapeutic targets. In recent years, the identification and / or characterization of the plasma membrane receptors for LPLs and enzymes regulating the metabolism of LPLs have greatly facilitated our understanding of their role and signaling properties. In vitro and in vivo functional and signaling studies have revealed the broad and potent biological effects of LPLs and the mechanisms of LPL actions in different cellular systems. Development of specific antagonists for each of the LPL receptors will provide powerful tools for dissecting signaling pathways mediated by receptor subtypes. More importantly, these antagonists may serve as therapeutics for relevant diseases. Genetic depletion of LPL receptors in mice has provided and will continue to provide critical information on the pathophysiological roles of LPL receptors. It is important to further evaluate the significance of targeting these bioactive LPL receptors, their downstream signaling molecules, and / or metabolic enzymes in the treatment of cancers and other diseases.
Keywords: lysophospholipids (lyso-pls), lysophosphatidic acid (lpa), sphingosine-1-phosphate (s1p), sphingosylphosphorylcholine (spc), lysophosphatidylinositol (lpi), lysophosphatidylcholine (lpc), ovarian cancer, g protein coupled receptors (gpcrs)
Current Drug Targets - Immune, Endocrine & Metabolic Disorders
Title: Unfolding the Pathophysiological Role of Bioactive Lysophospholipids
Volume: 3 Issue: 1
Author(s): Yan Xu, Yi-jin Xiao, Kui Zhu, Linnea M. Baudhuin, Jun Lu, Guiying Hong, Kwan-sik Kim, Kelly L. Cristina, Li Song and Freager S. Williams
Affiliation:
Keywords: lysophospholipids (lyso-pls), lysophosphatidic acid (lpa), sphingosine-1-phosphate (s1p), sphingosylphosphorylcholine (spc), lysophosphatidylinositol (lpi), lysophosphatidylcholine (lpc), ovarian cancer, g protein coupled receptors (gpcrs)
Abstract: Lysophospholipids (LPLs), including glycerol- and sphingoid-based lipids, stimulate cell signaling and play important pathophysiological roles in humans and other animals. These LPLs include lysophosphatidic acid (LPA), lysophosphatidylinositol (LPI), lysophosphatidylcholine (LPC), lysophosphatidylserine (LPS), sphingosine-1-phosphate (S1P), and sphingosylphosphorylcholine (SPC). Analyses of LPLs in human body fluids from subjects with different pathophysiological conditions reveal not only the relevance of LPLs in human diseases, but also their potential application as biomarkers and / or therapeutic targets. In recent years, the identification and / or characterization of the plasma membrane receptors for LPLs and enzymes regulating the metabolism of LPLs have greatly facilitated our understanding of their role and signaling properties. In vitro and in vivo functional and signaling studies have revealed the broad and potent biological effects of LPLs and the mechanisms of LPL actions in different cellular systems. Development of specific antagonists for each of the LPL receptors will provide powerful tools for dissecting signaling pathways mediated by receptor subtypes. More importantly, these antagonists may serve as therapeutics for relevant diseases. Genetic depletion of LPL receptors in mice has provided and will continue to provide critical information on the pathophysiological roles of LPL receptors. It is important to further evaluate the significance of targeting these bioactive LPL receptors, their downstream signaling molecules, and / or metabolic enzymes in the treatment of cancers and other diseases.
Export Options
About this article
Cite this article as:
Xu Yan, Xiao Yi-jin, Zhu Kui, Baudhuin M. Linnea, Lu Jun, Hong Guiying, Kim Kwan-sik, Cristina L. Kelly, Song Li and Williams S. Freager, Unfolding the Pathophysiological Role of Bioactive Lysophospholipids, Current Drug Targets - Immune, Endocrine & Metabolic Disorders 2003; 3 (1) . https://dx.doi.org/10.2174/1568005310303010023
DOI https://dx.doi.org/10.2174/1568005310303010023 |
Print ISSN 1568-0088 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5917 |
Related Articles
-
Poly(ADP-ribose) Polymerase-1 Inhibitor 3-Aminobenzamide Enhances Apoptosis Induction by Platinum Complexes in Cisplatin-Resistant Tumor Cells
Medicinal Chemistry Dimer and Tetramer of Gallic Acid: Facile Synthesis, Antioxidant and Antiproliferative Activities
Letters in Drug Design & Discovery Patented Biomarker Panels in Early Detection of Cancer
Recent Patents on Biomarkers Destabilizing Aneuploidy by Targeting Cell Cycle and Mitotic Checkpoint Proteins in Cancer Cells
Current Drug Targets The Role of Bone Density Measurements in the Evaluation of New Treatments for Osteoporosis
Current Pharmaceutical Design Synthesis and Anticancer Activities of New Benzothiadiazinyl Hydrazinecarboxamides and Anilino[1,2,4]triazolo[1,5-b][1,2,4]thiadiazine 5,5-diones
Medicinal Chemistry Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry Doing the Puzzle of Steroid Hormone Action: Biological Functions, Physiological and Clinical Significance of Plasma Membrane-Residing Glucocorticoid Recognizing Proteins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Metal Complexes of Natural Product Like-compounds with Antitumor Activity
Anti-Cancer Agents in Medicinal Chemistry Developments in the Application of 1,2,3-Triazoles in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Management of Ovarian Cancer In Younger Women
Reviews on Recent Clinical Trials Tyrosine Kinases as New Molecular Targets in Treatment of Inflammatory Disorders and Leukemia
Current Pharmaceutical Design The Non-Canonical IκB Kinases IKKε and TBK1 as Potential Targets for the Development of Novel Therapeutic Drugs
Current Molecular Medicine Reduced Nicotinamide Adenine Dinucleotide (NADH) Fluorescence for the Detection of Cell Death
Anti-Cancer Agents in Medicinal Chemistry Heparin, Heparan Sulfate and Heparanase in Cancer: Remedy for Metastasis?
Anti-Cancer Agents in Medicinal Chemistry Natural Polymers Based Hydrogels for Cell Culture Applications
Current Medicinal Chemistry CCR2 Antagonists
Current Topics in Medicinal Chemistry Targeting Karyotypic Complexity and Chromosomal Instability of Cancer Cells
Current Drug Targets Melatonin Regulates Angiogenic and Inflammatory Proteins in MDA-MB-231 Cell Line and in Co-culture with Cancer-associated Fibroblasts
Anti-Cancer Agents in Medicinal Chemistry